Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290, and 363 for substrate specificity

JA Hasler, GR Harlow, GD Szklarz, GH John, KM Kedzie, VL Burnett, YA He, LS Kaminsky and JR Halpert

Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson 85721.

Eleven amino acid residues unique to dog cytochrome P450 (P450) 2B11, compared with rat 2B1 and 2B2, rabbit 2B4 and 2B5, and mouse 2B10, in the putative substrate recognition sites [J. Biol. Chem. 267:83-90 (1992)] were mutated to the residues found in 2B1 or 2B5. The mutants were expressed initially in COS cells and screened for activity toward androstenedione and 2,2',4,4',5,5'-hexachlorobiphenyl (245-HCB). P450 2B11 mutants V107I, M199L-N200E-V204R, V234I, A292L, Q473R, and I475S showed no differences from wild-type P450 2B11 in metabolite profiles with either substrate. Mutants V114I, D290I, and L363V exhibited altered androstenedione metabolite profiles and were expressed in Escherichia coli for further study with androstenedione, testosterone, 7-ethoxycoumarin, (R)- and (S)-warfarin, and 245-HCB. With V114I, hydroxylation of steroids and warfarin and 2-hydroxylation of 245-HCB were decreased, whereas 7-ethoxycoumarin O-dealkylation and 3- hydroxylation of 245-HCB were unaltered. For D290I, activities toward all substrates were decreased, except for 16 beta-hydroxylation of testosterone. The activity of L363V was increased 5-6-fold for 16 alpha- hydroxylation of androstenedione and testosterone but was decreased to 40-50% of wild-type activity with 7-ethoxycoumarin and warfarin and to 6-8% of control for 2-hydroxylation of 245-HCB. Alignment of P450 2B11 with P450 101 and super-imposition of the 11 mutated 2B11 residues on a P450 101 three-dimensional model suggest that only residues 114, 290, and 363 represent substrate contact residues, in excellent agreement with the experimental results. The data indicate the importance of the three residues 114, 290, and 363 in substrate specificity and regio- and stereoselectivity of P450 2B11 and also demonstrate that the effects of the mutations vary considerably with different substrates.

Volume 46, Issue 2, pp. 338-345, 08/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				Y. Jounaidi, C.-S. Chen, G. J. Veal, and D. J. Waxman Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther., March 1, 2006; 5(3): 541 - 555. [Abstract] [Full Text] [PDF]

				S. Takahashi, Y. Zhao, P. E. O'Maille, B. T. Greenhagen, J. P. Noel, R. M. Coates, and J. Chappell Kinetic and Molecular Analysis of 5-Epiaristolochene 1,3-Dihydroxylase, a Cytochrome P450 Enzyme Catalyzing Successive Hydroxylations of Sesquiterpenes J. Biol. Chem., February 4, 2005; 280(5): 3686 - 3696. [Abstract] [Full Text] [PDF]

				E. E. Scott, M. A. White, Y. A. He, E. F. Johnson, C. D. Stout, and J. R. Halpert Structure of Mammalian Cytochrome P450 2B4 Complexed with 4-(4-Chlorophenyl)imidazole at 1.9-A Resolution: INSIGHT INTO THE RANGE OF P450 CONFORMATIONS AND THE COORDINATION OF REDOX PARTNER BINDING J. Biol. Chem., June 25, 2004; 279(26): 27294 - 27301. [Abstract] [Full Text] [PDF]

				C.-S. Chen, J. T. Lin, K. A. Goss, Y.-a. He, J. R. Halpert, and D. J. Waxman Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme Kinetics Mol. Pharmacol., May 1, 2004; 65(5): 1278 - 1285. [Abstract] [Full Text]

				T. L. Domanski, K. M. Schultz, F. Roussel, J. C. Stevens, and J. R. Halpert Structure-Function Analysis of Human Cytochrome P-450 2B6 Using a Novel Substrate, Site-Directed Mutagenesis, and Molecular Modeling J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1141 - 1147. [Abstract] [Full Text]

				J. C. Stevens, T. L. Domanski, G. R. Harlow, R. B. White, E. Orton, and J. R. Halpert Use of the Steroid Derivative RPR 106541 in Combination with Site-Directed Mutagenesis for Enhanced Cytochrome P-450 3A4 Structure/Function Analysis J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 594 - 602. [Abstract] [Full Text]

				S. M. Strobel, G. D. Szklarz, Y. q. He, M. Foroozesh, W. L. Alworth, E. S. Roberts, P. F. Hollenberg, and J. R. Halpert Identification of Selective Mechanism-Based Inactivators of Cytochromes P-450 2B4 and 2B5, and Determination of the Molecular Basis for Differential Susceptibility J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 445 - 451. [Abstract] [Full Text]

				G. R. Harlow and J. R. Halpert Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4. ROLE OF RESIDUES 210AND 211IN FLAVONOID ACTIVATION AND SUBSTRATE SPECIFICITY J. Biol. Chem., February 28, 1997; 272(9): 5396 - 5402. [Abstract] [Full Text] [PDF]

				G. C. Ibeanu, B. I. Ghanayem, P. Linko, L. Li, L. G. Pedersen, and J. A. Goldstein Identification of Residues 99, 220, and 221 of Human Cytochrome P450 2C19 as Key Determinants of Omeprazole Hydroxylase Activity J. Biol. Chem., May 24, 1996; 271(21): 12496 - 12501. [Abstract] [Full Text] [PDF]